492447-54-8
Chemical Structure
Fexapotide
Synonym(s): NX-1207
- CAS No.: 492447-54-8
- Formula:C90H163N27O25S
- Molecular Weight:2055.49
IUPAC Name: 7,8-dimethoxy-3-(3-(methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one hydrochloride
InChIKey: BROGCIMRGWLMOO-SJPGHYFNSA-N
SMILES: O=C(N[C@@H](CC(O)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CCCNC(N)=N)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CS)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)N
Biological Activity: Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fexapotide | Fexapotide (NX-1207) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Shore N, et al. Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. Ther Adv Urol. 2019 Jan 14;11:1756287218820807. [Content Brief]
- [2]. Shore N, et al. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol. 2018 May;36(5):801-809. [Content Brief]
- [3]. Shore N, et al. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011 Nov;2(6):377-83. [Content Brief]
Keywords
